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Abstract
The ancient product honey produced by honeybees, particularly the species Apis mellifera from the nectar
blossoms or from exudates of trees and plants. Honey contains a very high content of carbohydrates, mostly mono-
and disaccharides but it also contains many members of the family of antioxidant flavonoids. Over the last several
decade of studies on human disease processes it has become recognized that an elevated, unfavourable oxidation
status and a states of chronic inflammation underlies multiple diseases most notably, cardiovascular disease (CVD).
The underlying cause of most CVD is atherosclerosis, the trapping of lipids in the vessel wall by modified
proteoglycans, followed by oxidation, a chronic immune response and the development and rupture of
atherosclerotic plaques. Many of the flavonoids present in honey have actions which impact on the oxidative and
other processes of atherosclerosis. In this review we describe the actions of many of the flavonoids present in honey
and speculate on the manner in which these might aggregate to produce a favorable CVD protective effect of honey
per se.
Keywords: Honey; Flavonoids; Anti-oxidants; Atherosclerosis;
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Introduction
Honey is a natural substance with a sweet flavour and viscous
consistency that is produced by honeybees, particularly the species
Apis mellifera [1], from the nectar blossoms or from exudates of trees
and plants that produce nectar honeys or honeydews, respectively [2].
Different types of honey samples contain a number of flavonoids
including catechin, quercetin, rutin, naringin, naringenin, kaempferol,
apigenin, chrysin, acacetin, luteolin, myricetin, hesperitin,
galanginsome of which have evolved as promising pharmacological or
even therapeutic agents [3]. Flavonoids have been recognized as
compounds with potent biological activities that may be active in the
prevention of chronic diseases including atherosclerosis and
cardiovascular diseases (CVDs) [4].
CVD is the largest single cause of premature mortality in developed
countries and its underlying pathology is atherosclerosis [5]. An
important initiating event for atherosclerosis is the transport of low-
density lipoproteins (LDLs) across the endothelium into the artery wall
[6]. Intimal lipids are trapped by modified proteoglycans with
hyperelongated glycosaminoglycan (GAG) chains [7-9], the oxidation
of the neointimal lipids leads to the release of oxidized immunogenic
molecular species which initiate a chronic inflammatory process in the
vessel wall.
Flavonoids have been reported to be potentially active in
cardiovascular prevention mainly by decreasing oxidative stress and
increasing nitric oxide (NO) bioavailability. These polyphenolic
compounds are able to modulate the expression of genes associated
with metabolism, stress defence, drug metabolizing enzymes, and
detoxification and transporter proteins [10-12]. Their overall effect is
protective in overcoming the deleterious effects of cardiovascular risk
factors and in delaying the onset of atherosclerosis [13]. In this review,
we considered the prominent honey flavonoids and their biological
and pharmacological actions in the prevention and treatment of
atherosclerosis and CVDs.
Flavonoids have several anti-atherosclerotic activities including
anti-inflammatory, antioxidant, anti-proliferative and antiplatelet
activities. Cholesterol-lowering and anti-hypertensive effects of
flavonoids have also been described [4]. The central component of the
oxidation hypothesis of atherogenesis is that oxidative modification of
LDLs provides an immunogenic stimulus for monocyte recruitment to
the vessel wall and phagocytic uptake of oxidized LDL by macrophages
[14]. Extensive oxidation of LDLs leads to its aggregation [15,16] and
that both of these modified forms of LDLs are present in the
atherosclerotic lesion. Recent studies demonstrated that catechin and
quercetin (two major honey flavonoids) [3,17] consumption exhibited
inhibitory effect on development of aortic atherosclerotic lesions and
on atherogenic modification of LDLs [18]. NO, produced by
endothelial nitric oxide synthase (eNOS), is a major anti-atherogenic
factor in the blood vessel. Oxidative stress plays an important role in
the pathogenesis of CVDs including atherosclerosis. Decreased
availability of endothelial NO promotes the progression of endothelial
dysfunction and atherosclerosis. Rutin promotes NO production by
inducing eNOS gene expression, eNOS protein synthesis and eNOS
activity. Treatment with rutin also leads to increased gene and protein
expression of basic fibroblast growth factor (bFGF). Therefore, up-
regulation of eNOS expression by rutin may be mediated by bFGF
[18]. The honey-derived flavonoid naringin inhibits
hypercholesterolemia-induced intercellular adhesion molecule-1
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(ICAM-1) expression on endothelial cells. Hypercholesterolemia
causes fatty liver and an elevation of liver enzymes, effects which are
prevented by naringin. Naringin also reduces fatty streak formation
and neointimal macrophage infiltration and also inhibits the
expression of ICAM-1 in endothelial cells, suggesting that suppression
of ICAM-1 contributes to its vascular effects [19]. Naringenin
decreases LDL and triglycerides levels as well as inhibiting glucose
uptake, increase high density lipoproteins (HDLs), co-oxidation of
NADH, suppression of protein oxidation, suppression macrophage
inflammation, inhibits leukotriene B4 leading to reduced monocyte
adhesion and foam cell formation and the down-regulate genes related
to atherosclerosis [20]. Apigenin, commonly found in honey, improves
various parameters of cardiovascular disease, stimulates the favorable
aspects of the immune system and inhibits platelet aggregation [21].
Apigenin exhibits a pro-apoptotic effect on oxidized LDL (Ox LDL)-
loaded murine peritoneal macrophages (MPMs) and increases the
expression of pro-apoptotic Bax, cleaves caspase-3and it decreases the
anti-apoptotic factors Mcl-1 and Bcl-2 (Figure 1). These results
suggested that the anti-atherosclerotic effects of apigenin are associated
with the up-regulation of apoptosis in OxLDL-loaded MPMs [22].
Figure 1: Potential anti-atherosclerotic effects of honey-derived flavonoids.
Atherosclerosis is widely considered to be a chronic inflammatory
disease of the vessel wall and as such adhesion molecules which attract
and stimulate infiltration of inflammatory cells play an important role
in atherogenesis. A honey flavonoid kaempferol shows effects in this
area by modulating the gene and protein expression of inflammatory
molecules [23]. The honey flavonoid chrysin possesses multiple
pharmacological activities some of which in the current context would
be seen as anti-atherosclerotic. Chrysin is an inhibitor of foam cell
formation that may stimulate cholesterol flow. Up-regulation of the
classical peroxisome proliferator-activated receptor gamma (PPARγ)-
liver X receptor alpha (LXR-α)-ATP-binding cassette, sub-family A1
(ABCA 1)/ATP-binding cassette, sub-family G1 (ABCG1) pathway
and down-regulation of scavenger receptor A1 (SR-A1) and SR-A2
may participate the suppressive effect of chrysin on intracellular
cholesterol accumulation thereby reducing the development of
atherosclerosis [24]. Although many honey-derived flavonoids have
actions which inhibit processes considered to be associated with the
development of atherosclerosis, it is plausible that, through
pharmacological synergy, these honey flavonoids might be confer an
anti-atherosclerotic on honey per se.
Flavonoids decrease the risk of CVDs by improving coronary
vasodilatation, decreasing the ability of platelets to clot and preventing
LDLs from oxidizing [3]. CVDs involve multifactorial processes
involving oxidative stress [25], abnormalities in lipid metabolism [26],
disturbances in vascular tone platelet aggregation inflammation [27]
and proliferation of vascular cells [28]. Catechin beneficially impacts
many of these parameters including vascular dysfunction, including
lipoprotein oxidation, blood platelet aggregation, vascular
inflammation, vascular smooth muscle cell (VSMC) proliferation,
altered lipid profile and vascular reactivity. Besides being antioxidants,
catechins exert biological effects by modulating some cellular signaling
pathways that lead to a reduction in inflammation, platelet
aggregation, and an elevation of vascular reactivity [29]. The sources
for the reactive oxygen species (ROS) production during CVD are
uncoupling of mitochondrial electron transport, pro-inflammatory
cytokines and induction of oxidative enzymes such as inducible nitric
oxide synthase (iNOS) and xanthine oxidase (XO) [30]. Honey exerts
is cardio protective effect mainly through antioxidant activities of
catechin including ROS scavenging, chelating redox active transition-
metal ions, inhibiting redox sensitive transcription factors, inhibiting
pro-oxidant enzymes and inducing antioxidant enzymes [31,32].
Hyperlipidemia, resulting from the abnormalities of lipid metabolism,
is one of the major risk factors for the development of CVDs. The
elevated levels of plasma lipids such as fatty acids, cholesterol,
phospholipids and triglycerides the accelerated development of
atherosclerotic plaques. Catechins reduce blood cholesterol levels and
prevent the deposition and/or accumulation of cholesterol in various
tissues including liver and heart. The phenomena of endothelial
dysfunction, mostly reduced availability of NO but also other factors, is
widely associated with the pathogenesis and the precipitation of the
clinical manifestations of CVDs. Experimental and clinical studies
have shown that catechins improve endothelial function [29].
Quercetin is a naturally occurring flavonoid that exerts multiple
pharmacological effects. Yoshizumi et al. [33] proposed that daily
intake of bioflavonoids reduces the incidence of ischemic heart disease
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(IHD). It was hypothesized that bioflavonoids may affect angiotensin-
II (Ang-II)-induced MAP (mitogen activated protein) kinase
activation in cultured rat aortic smooth muscle cells (RASMC). Ang-II
stimulated rapid activation of extracellular signal-regulated kinase
(ERK) 1/2, c-Jun N-terminal kinase (JNK), and p38 in RASMC. Ang-II
induced JNK activation was inhibited by quercetin, whereas ERK1/2
and p38 activation by Ang-II were not affected by quercetin. Ang-II
caused a rapid tyrosine phosphorylation of Src, which was inhibited by
quercetin. This flavonoid compound also activated the PI3K/Akt
pathway in RASMC. Moreover, a PI3K inhibitor and quercetin
derivative inhibited Ang-II-induced JNK activation as well as Akt
phosphorylation. These findings suggested that the inhibitory effect of
quercetin on Ang-II-induced vascular smooth muscle cell (VSMC)
hypertrophy are attributable, in part, to its inhibitory effect on PI3K-
dependent JNK activation in VSMC. Therefore, inhibition of JNK by
quercetin may imply its usefulness for the treatment of cardiovascular
diseases (CVDs). Naringin shows a range of properties that help
protect the cardiovascular system, including anti-hypertensive, lipid
lowering, insulin-sensitizing, antioxidative and anti-inflammatory
properties [34]. Naringin prevents the age-related increase in systolic
blood pressure in stroke-prone spontaneously hypertensive rats,
increases NO production, improves endothelial function and decreases
cerebral thrombosis [35]. Further, naringin prevents oxidative stress in
the hearts of rats with isoprenaline-induced myocardial infarction
(MI) [36]. Another bioflavonoid, naringenin, is present in many honey
types [37]. Naringenin inhibits the TNFα induced VSMC proliferation
and migration, which is an important event in the generation of a
neointima and in the restenosis following vascular injury or luminal
reconstruction [38]. Naringenin also blocks the increased ROS
generation induced by TNF-α. Oxidative stress and TNFα trigger the
activation of MAP kinases, which are key regulatory factors for VSMC
proliferation. Naringenin prevents ERK/MAP kinase and Akt
phosphorylation, whereas p38 MAP kinase and JNKs remained
unchanged. This overall effect is probably mediated via the induction
of heme oxygenase 1 (HO-1) and reduction in oxidative stress [39].
Galangin has anti-oxidative effect on endothelial tissues, thus affects
lipid peroxidation another favorable effect for the amelioration of
CVD. Galangin has an interesting action to preserve other protective
anti-oxidants such as vitamin E, vitamin C and other flavonoids. In
CVDs, the protective effects of honey flavonoids include mainly anti-
thrombotic, anti-ischemic, antioxidant and vasorelaxant [40].
Flavonoids in honeys along with other polyphenolic components and
enzymes are the responsible elements for the favorable effects on the
prevention and potentially the treatment of CVDs.
In recent years, the prevention of CVDs and its underlying cause
atherosclerosis have been associated with the consumption of fresh
fruits, vegetables or plants rich in natural antioxidants, because of the
attractive features of such a strategy relative to the use of synthetic
products [41,42]. Honey, a natural sweetener, therefore can be
considered as a natural therapy against atherosclerosis and CVDs.
Overall, the probable mechanisms by which honey exhibits its
protective and curative actions against myocardial damage are via
improved anti-oxidative status and lowered plasma cholesterol level. It
might be concluded that major contributing agents of cardio protective
and anti-atherosclerotic effects of honey are flavonoid constituents
commonly present in natural honeys.
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